ORIFARM GENERICS A/S: Financial statements 2023
CVR: 25674030
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
ORIFARM GENERICS A/S (CVR 25674030) has filed annual accounts for 2023. In 2023, the company reported revenue of DKK 2,137,930,000 and a net result of DKK 62,928,000 compared with DKK 54,462,000 the year before. That is an increase of 3% compared with the year before. The profit margin was 2.9%. Equity in the 2023 report amounted to DKK 494,647,000. The solvency ratio was 35.8%. The company had 289 employees in the financial year.
- Revenue
- DKK 2,137,930,000
- Gross Profit
- DKK 344,529,000
- Profit/Loss
- DKK 62,928,000
- Equity
- DKK 494,647,000
- Total Assets
- DKK 1,382,406,000
- Employees
- 289
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | 2.1B | 344.5M | 62.9M | 494.6M | 289 |
| 2022 | 2.1B | 261.5M | 54.5M | 431.7M | 228 |
| 2021 | 1.8B | 329.3M | 150.1M | 527.3M | 181 |
| 2020 | 688.4M | 274.2M | 145.5M | 201.2M | 117 |
| 2019 | 545M | 197M | 103.9M | 145.7M | 99 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
ORIFARM GENERICS A/S has published its annual report for 2022. Revenue came to DKK 2,074,832,000, and the net result was DKK 54,462,000.
About ORIFARM GENERICS A/S
ORIFARM GENERICS A/S is a Danish company of the type Aktieselskab based in Odense S, founded in 2000. The company is registered under the industry Engroshandel med læge- og hospitalsartikler. The company was previously named COPYFARM A/S and A/S PSE 38 NR. 2228. The management consists of Thomas Brandhof. The board consists of Hans Carl Bøgh-Sørensen (chair), Birgitte Bøgh-Sørensen, Mads Fink Eriksen and Nicki Lund Kristensen. The company is owned by ORIFARM GENERICS HOLDING A/S. The company has 255 employees (2026). In 2025, the company reported revenue of DKK 2,463,585,000 and a net result of DKK 77,177,000 compared with DKK 59,860,000 the year before. Equity in the 2025 report amounted to DKK 496,304,000.